GSK profit misses as Shingrix disappoints, stockpiling eases
July 29 (Reuters) - Britain's GSK GSK.L fell short of quarterly expectations for profit on Wednesday, as sales of the drugmaker's blockbuster shingles vaccine fell and stockpiling of pain and lung medication tapered as countries eased lockdowns.
Turnoverfell 3% to 7.62 billion pounds in the three months ended June 30 on a constant currency basis, while adjusted earnings stood at 19.2 pence per share, the company said. GSK maintained its 2020 forecast.
Fourteen analysts on average expected second-quarter adjusted earnings of 20.1 pence per share and sales of 7.72 billion pounds, according to a company-compiled consensus.
PREVIEW-U.S. drugmaker earnings heat up this week with spotlight on vaccine news
GSK aims for 1 bln doses of booster as COVID-19 vaccine race heats up
GSK in quest to be best, not first, in race for COVID-19 vaccine
GSK begins U.S. test of experimental drug for pneumonia from COVID-19
GSK to test experimental drug to treat pneumonia from COVID-19
FACTBOX-Worldwide coronavirus cases
FACTBOX-The race for a coronavirus vaccine
FACTBOX-Drugmakers rush to develop COVID-19 treatments
GRAPHIC-Tracking and explaining the new coronavirushttps://tmsnrt.rs/2GVwIyw
(Reporting by Pushkala Aripaka, Ankur Banerjee in Bengaluru and Ludwig Burger in Frankfurt; Editing by Bernard Orr)
((Pushkala.A@thomsonreuters.com; Twitter: @pullthekart; within UK: +44 20 7542 1810, outside UK: +91 80 6182 2600; Mobile: +91 852 751 3793;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.